Overall, this study demonstrated that Vδ2 T cells can successfully inhibit NPC tumor growth when the hurdle of sufficient BTN2A1/BTN3A1 expression are overcame by use of the EBV-reactivating agent (L2)P4. Here, BTN3A1 is linked to nasopharyngeal carcinoma.